BioLife Solutions, Inc. $BLFS Stock: CenterBook Partners LP Decreases Holdings

CenterBook Partners LP trimmed its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 81.5% during the third quarter, Holdings Channel.com reports. The fund owned 9,946 shares of the medical equipment provider’s stock after selling 43,822 shares during the quarter. CenterBook Partners LP’s holdings in BioLife Solutions were worth $386,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Oregon Public Employees Retirement Fund boosted its holdings in BioLife Solutions by 7.8% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 9,685 shares of the medical equipment provider’s stock valued at $376,000 after purchasing an additional 700 shares during the period. ProShare Advisors LLC bought a new position in shares of BioLife Solutions during the third quarter worth approximately $683,000. Transmarket Holdings LP bought a new position in shares of BioLife Solutions during the third quarter worth approximately $5,366,000. Yousif Capital Management LLC increased its holdings in shares of BioLife Solutions by 4.9% during the third quarter. Yousif Capital Management LLC now owns 11,097 shares of the medical equipment provider’s stock worth $431,000 after purchasing an additional 520 shares during the period. Finally, Kings Path Partners LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at approximately $644,000. 93.24% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BLFS shares. Weiss Ratings upgraded BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Craig Hallum downgraded BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a research report on Wednesday, July 22nd. Jefferies Financial Group lowered BioLife Solutions from a “buy” rating to a “hold” rating and raised their price objective for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. HC Wainwright cut BioLife Solutions from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $32.00 to $31.00 in a report on Thursday, July 23rd. Finally, William Blair set a $31.00 target price on BioLife Solutions in a research report on Thursday, July 23rd. One research analyst has rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Hold” and a consensus target price of $31.38.

BioLife Solutions Price Performance

BLFS opened at $38.61 on Friday. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.82. BioLife Solutions, Inc. has a twelve month low of $17.86 and a twelve month high of $39.76. The company has a 50-day simple moving average of $37.87 and a 200 day simple moving average of $28.57.

About BioLife Solutions

BioLife Solutions, Inc. develops and supplies products and services used in the development and commercial production of cell and gene therapies and other biologic medicines. Its offerings support the handling, preservation, storage and distribution of sensitive biological materials. The company’s products include CryoStor and HypoThermosol preservation media, as well as CellSeal bags designed for cryogenic storage. BioLife also provides temperature-controlled storage and repository services for biological materials through its SciSafe business.